Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting

Background Current strategies for risk stratification of patients with acute myeloid leukemia assign approximately 40% of patients to the intermediate-risk group, where uncertainty about optimal therapy still persists. Objective The objective of this study was to assess the cost effectiveness of a H...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Applied health economics and health policy 2019-12, Vol.17 (6), p.827-839
Hauptverfasser:	Tremblay, Gabriel, Rousseau, Ben, Marquis, Miriam, Beaubois, Cyrielle, Sauvageau, Guy, Hébert, Josée
Format:	Artikel
Sprache:	eng
Schlagworte:	Chemotherapy Cost analysis Cost control Cytogenetics Effectiveness Health Administration Health care Health care expenditures Health Economics Health risk assessment Health services Leukemia Medical prognosis Medical treatment Medicine Medicine & Public Health Mutation Original Original Research Article Patients Pharmacoeconomics and Health Outcomes Public Health Quality of Life Research Remission (Medicine) Risk Sensitivity analysis Standard of care Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!